Search form

Donald P. Paradiso

Las Vegas

P 702-921-2460
F 702-921-2461


Donald (Don) P. Paradiso is an Associate in the Las Vegas, Nevada, office of Jackson Lewis P.C. His practice focuses on representing employers in workplace law matters, including complex class action litigation, wage/hour cases, discrimination matters, and providing advice and counsel.

Mr. Paradiso has achieved victories for clients at every judicial level in the Ninth Circuit, including published case law from the Ninth Circuit Court of Appeals. Mr. Paradiso has experience appearing before judicial departments, administrative law judges, and has first chair trial experience. While attending law school, Mr. Paradiso was a Senior Editor on the Penn State International Law Review, where his article on international piracy, maritime law, and its impact on global shipping was selected for publication. Mr. Paradiso was also a member of a four-person team competing in the prestigious Willem C. Vis Commercial Arbitration Moot in Vienna, Austria.

Prior to joining Jackson Lewis, Mr. Paradiso served as counsel at a national firm focusing on commercial litigation and employment matters. He was also law clerk for the Honorable Vincent Ochoa in the Eighth Judicial District Court.

Honors and Recognitions

  •, Rated “Superb” – 9.6/10.0
  • Nevada Business Magazine, "Legal Elite" (2019)
Donald P. Paradiso
Rated by Super Lawyers

loading ...

Professional Associations and Activities

  • State Bar of Nevada, Fee Dispute Committee, Mediator and Arbitrator

Pro Bono and Community Involvement

  • Office of Military Legal Assistance, Pro Bono Counsel

See AllBlog Posts by Donald P. Paradiso

Occupations Governed by Federal Regulation Remain Guarded Against State Medical Marijuana Non-Discrimination Laws
June 11, 2019

A growing number of states have passed anti-discrimination laws pertaining to medical marijuana use. While medical marijuana is becoming widely legalized under state law, marijuana and its most identifiable active chemical, THC, remain listed as Schedule I drugs under the federal Controlled Substances Act. Read More